Karachi: Abbott Laboratories (Pakistan) Limited has announced a forthcoming meeting of its Board of Directors set for April 28, 2025. The primary agenda for this meeting will be to review and consider the company's Quarterly Accounts for the period ending March 31, 2025.

In alignment with regulatory requirements, Abbott Laboratories (Pakistan) Limited has instituted a "Closed Period," commencing on April 21, 2025, and concluding on April 28, 2025. During this timeframe, as stipulated under Clause 5.6.4 of the Pakistan Stock Exchange (PSX) Regulations, no Director, Chief Executive Officer, or Executive of the company is permitted to engage, either directly or indirectly, in trading the company's shares.

According to information available from the Pakistan Stock Exchange (PSX), this measure is intended to maintain transparency and prevent any potential insider trading activity during the preparation and evaluation of the company's financial statements. The company's adherence to these regulations underscores its commitment to regulatory compliance.

The company has communicated these developments to the TRE Certificate Holders of the Exchange, ensuring that all relevant parties are informed of the trading restrictions in place during the specified period.